1036765-54-4Relevant academic research and scientific papers
HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigation
De Luca, Laura,De Grazia, Sara,Ferro, Stefania,Gitto, Rosaria,Christ, Frauke,Debyser, Zeger,Chimirri, Alba
experimental part, p. 756 - 764 (2011/03/20)
This study is focused on a new series of benzylindole derivatives with various substituents at the benzene-fused ring, suggested by our 3D pharmacophore model developed for HIV-1 integrase inhibitors (INIs). All synthesized compounds proved to be active in the nanomolar range (6-35 nM) on the strand-transfer step (ST). In particular, derivative 4-[1-(4-fluorobenzyl)- 5,7-dimethoxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid (8e), presenting the highest best-fit value on pharmacophore model, showed a potency comparable to that of clinical INSTIs GS 9137 (1) and MK-0518 (2). The binding mode of our molecules has been investigated using the recently published crystal structure of the complex of full-length integrase from the prototype foamy virus in complex with its cognate DNA (PFV-IN/DNA). The results highlighted the ability of derivative 8e to assume the same binding mode of MK-0518 and GS 9137.
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series
De Luca, Laura,Barreca, Maria Letizia,Ferro, Stefania,Iraci, Nunzio,Michiels, Martine,Christ, Frauke,Debyser, Zeger,Witvrouw, Myriam,Chimirri, Alba
, p. 2891 - 2895 (2008/12/21)
We report herein the development of a new three-dimensional pharmacophore model for HIV-1 integrase inhibitors which led to the discovery of some 4-[1-(4-fluorobenzyl)-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acids that are able to specifically inhibit the strand transfer step of integration at nanomolar concentration. The synthesis of the new designed molecules is also described.
